...
首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair-Deficient Cancers.
【24h】

Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair-Deficient Cancers.

机译:并行的高通量RNA干扰筛查将PINK1确定为治疗DNA错配修复缺陷型癌症的潜在治疗靶标。

获取原文
获取原文并翻译 | 示例
           

摘要

Synthetic lethal approaches to cancer treatment have the potential to deliver relatively large therapeutic windows and therefore significant patient benefit. To identify potential therapeutic approaches for cancers deficient in DNA mismatch repair (MMR), we have carried out parallel high-throughput RNA interference screens using tumor cell models of MSH2- and MLH1-related MMR deficiency. We show that silencing of the PTEN-induced putative kinase 1 (PINK1), is synthetically lethal with MMR deficiency in cells with MSH2, MLH1, or MSH6 dysfunction. Inhibition of PINK1 in an MMR-deficient background results in an elevation of reactive oxygen species and the accumulation of both nuclear and mitochondrial oxidative DNA lesions, which likely limit cell viability. Therefore, PINK1 represents a potential therapeutic target for the treatment of cancers characterized by MMR deficiency caused by a range of different gene deficiencies. Cancer Res; 71(5); 1836-48. (c)2011 AACR.
机译:癌症的综合致命治疗方法有可能提供相对较大的治疗窗口,因此可为患者带来可观的收益。为了确定缺乏DNA错配修复(MMR)的癌症的潜在治疗方法,我们使用MSH2和MLH1相关MMR缺乏症的肿瘤细胞模型进行了平行的高通量RNA干扰筛查。我们显示沉默的PTEN诱导的假定激酶1(PINK1),在具有MSH2,MLH1或MSH6功能障碍的细胞中,由于MMR缺乏而致死。在MMR缺乏的背景下抑制PINK1会导致活性氧的增加以及核和线粒体氧化DNA损伤的积累,这很可能会限制细胞的活力。因此,PINK1代表了潜在的治疗靶标,用于治疗以一系列不同基因缺陷引起的MMR缺乏为特征的癌症。癌症研究; 71(5); 1836-48。 (c)2011年美国机修协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号